aTYR PHARMA INC Operating Lease, Expense
aTYR PHARMA INC (ATYR) reported Operating Lease, Expense of $400.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-08-07
- aTYR PHARMA INC operating lease, expense for the quarter ending 2026-06-30 was $400.00K, a 0.00% change year-over-year.
- aTYR PHARMA INC operating lease, expense for the quarter ending 2026-03-31 was $400.00K, a 0.00% change year-over-year.
- aTYR PHARMA INC operating lease, expense for the quarter ending 2025-12-31 was $300.00K, a 25.00% decline year-over-year.
- aTYR PHARMA INC operating lease, expense for the quarter ending 2025-09-30 was $400.00K, a 0.00% change year-over-year.
- aTYR PHARMA INC operating lease, expense for fiscal 2025 was $1.50M, a 0.00% change from fiscal 2024.
- aTYR PHARMA INC operating lease, expense for fiscal 2024 was $1.50M, a 21.05% decline from fiscal 2023.
- aTYR PHARMA INC operating lease, expense for fiscal 2023 was $1.90M, a 26.67% increase from fiscal 2022.
- aTYR PHARMA INC operating lease, expense for fiscal 2022 was $1.50M, a 50.00% increase from fiscal 2021.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $400.00K 10-Q · filed 2026-08-07 | $800.00K 10-Q · filed 2026-08-07 | $1.10M derived: sum of 3 quarters · filed 2026-08-07 | $1.50M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $400.00K 10-Q · filed 2026-05-15 | $700.00K derived: sum of 2 quarters · filed 2026-05-15 | $1.10M derived: sum of 3 quarters · filed 2026-05-15 | $1.50M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $700.00K derived: sum of 2 quarters · filed 2026-03-05 | $1.10M derived: sum of 3 quarters · filed 2026-08-07 | $1.50M 10-K · filed 2026-03-05 |
| 2025-09-30 | $400.00K 10-Q · filed 2025-11-06 | $800.00K derived: sum of 2 quarters · filed 2026-08-07 | $1.20M 10-Q · filed 2025-11-06 | $1.60M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $400.00K 10-Q · filed 2026-08-07 | $800.00K 10-Q · filed 2026-08-07 | $1.20M derived: sum of 3 quarters · filed 2026-08-07 | $1.60M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $400.00K 10-Q · filed 2026-05-15 | $800.00K derived: sum of 2 quarters · filed 2026-05-15 | $1.20M derived: sum of 3 quarters · filed 2026-05-15 | $1.60M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $800.00K derived: sum of 2 quarters · filed 2026-03-05 | $1.20M derived: sum of 3 quarters · filed 2026-03-05 | $1.50M 10-K · filed 2026-03-05 |
| 2024-09-30 | $400.00K 10-Q · filed 2025-11-06 | $800.00K derived: sum of 2 quarters · filed 2025-11-06 | $1.10M 10-Q · filed 2025-11-06 | $1.60M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-06-30 | $400.00K 10-Q · filed 2025-08-07 | $700.00K 10-Q · filed 2025-08-07 | $1.20M derived: sum of 3 quarters · filed 2026-03-05 | $1.50M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-03-31 | $300.00K 10-Q · filed 2025-05-07 | $800.00K derived: sum of 2 quarters · filed 2026-03-05 | $1.10M derived: sum of 3 quarters · filed 2026-03-05 | $1.60M derived: sum of 4 quarters · filed 2026-03-05 |
| 2023-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $800.00K derived: sum of 2 quarters · filed 2026-03-05 | $1.30M derived: sum of 3 quarters · filed 2026-03-05 | $1.90M 10-K · filed 2026-03-05 |
| 2023-09-30 | $300.00K 10-Q · filed 2024-11-07 | $800.00K derived: sum of 2 quarters · filed 2024-11-07 | $1.40M 10-Q · filed 2024-11-07 | $2.20M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-06-30 | $500.00K 10-Q · filed 2024-08-13 | $1.10M 10-Q · filed 2024-08-13 | $1.90M derived: sum of 3 quarters · filed 2025-03-13 | $2.20M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-03-31 | $700.00K 10-Q · filed 2024-05-02 | $1.40M derived: sum of 2 quarters · filed 2025-03-13 | $1.70M derived: sum of 3 quarters · filed 2025-03-13 | $1.90M derived: sum of 4 quarters · filed 2025-03-13 |
| 2022-12-31 | $700.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $1.00M derived: sum of 2 quarters · filed 2025-03-13 | $1.20M derived: sum of 3 quarters · filed 2025-03-13 | $1.50M 10-K · filed 2025-03-13 |
| 2022-09-30 | $300.00K 10-Q · filed 2023-11-09 | $500.00K derived: sum of 2 quarters · filed 2023-11-09 | $800.00K 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $200.00K 10-Q · filed 2023-08-09 | $500.00K 10-Q · filed 2023-08-09 | ||
| 2022-03-31 | $200.00K 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | $1.00M 10-K · filed 2024-03-14 | |||
| 2020-12-31 | $1.00M 10-K · filed 2023-03-14 | |||
| 2019-12-31 | $1.00M 10-K · filed 2022-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |